NHD Global
Metabolic & Weight Loss · GIP/GLP-1 research
Scientific Product Dossier
Tirzepatide is a peptide that activates two hormone receptors, GIP and GLP-1. These signals help explain research into appetite, body weight and glucose control. Large human trials tested regulated drug preparations, not NHD research vials. This page explains the measured results in plain language and keeps them separate from the identity, specifications and document status of catalog material. For a research quotation, select the relevant variant and tell us the amount and records you need.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
In adults with obesity or overweight without diabetes, mean weight reductions were 15.0%, 19.5% and 20.9% across the three tirzepatide groups, versus 3.1% with placebo.
These are study-group averages. Gastrointestinal events were common. The intervention and monitoring in the trial are different from catalogue research material.
Read the primary studyIn 1,879 adults with type 2 diabetes, HbA1c fell by 2.01, 2.24 and 2.30 percentage points across tirzepatide groups, versus 1.86 points with the studied semaglutide comparator.
HbA1c reflects average glucose over roughly two to three months. The comparison applies to this trial’s regimens and population, not every product or patient.
Read the primary studyThe current FDA label identifies tirzepatide as a GIP/GLP-1 receptor agonist and records initial U.S. approval in 2022.
Approval applies only to the named regulated drug product and presentation, not to third-party research material.
Read the primary studyCurrent U.S. labeling includes a boxed warning based on thyroid C-cell tumor findings in rats, contraindications and common gastrointestinal adverse reactions.
This safety information belongs to the named regulated finished drug; it neither validates nor characterizes third-party catalog material.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 15 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 20 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 30 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 40 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 50 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 60 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 100 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 120 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Randomized, double-blind, placebo-controlled human research over 72 weeks. Results are clinical evidence for the studied intervention, not a specification for this catalog lot.
View primary recordAuthoritative pharmacology and approval context for a regulated branded medicine. The research catalog remains physically and legally distinct.
View primary recordThird-party publications selected for direct relevance.
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
U.S. Food and Drug Administration. Revised December 2025. Initial U.S. approval 2022.
U.S. Food and Drug Administration. Current Drugs@FDA label for NDA 217806.
Concise answers for researchers comparing identity, evidence and catalog variants.
In human trials, the tested drug produced substantial, lasting weight loss in adults with obesity and improved long-term blood-sugar control in adults with type 2 diabetes. These effects are linked to GIP and GLP-1 receptor activation. The evidence comes from regulated medicines tested under specific protocols, not from catalog research material.
The approved-drug label describes increased insulin release when blood sugar is high and reduced glucagon, a hormone that raises blood sugar. This supports blood-sugar control in people with type 2 diabetes. The clinical effects are established for the regulated medicine, not for third-party research compounds.
The effects discussed here are reduced appetite and food intake, weight reduction and improved blood-sugar control. The evidence concerns approved medicines and clinical trial interventions, not NHD research vials.
Not when the numbers come from separate trials. Different participants, follow-up periods and analyses can change the results. A direct comparison needs an appropriate head-to-head study.
No. FDA approval applies to specific regulated branded products. This catalog entry is research, development and manufacturing material only.
Tell us which records your project requires. Availability and scope must be confirmed for the selected material. Published papers are not batch certificates, and this page does not confirm that a lot-specific COA is available.
Request the storage conditions for the exact supplied form and selected variant. A temperature stated for another supplier or a clinical drug preparation is not a verified storage specification for NHD catalog material.
No. A trial tests a defined preparation in a defined population, with a protocol and monitoring. Catalog material must be evaluated for its own identity and research specifications. A published clinical result does not verify a supplied batch.
Send the exact product name, selected catalog variant, required quantity, destination and documents needed for the project. Specify whether the amount refers to powder mass or measured peptide content. Availability, price, lead time and document scope require confirmation.
No. A paper describes the material and methods used in that study. It does not establish the identity, purity or content of a different supplied lot. Ask which records actually apply to the requested material; do not assume a COA is available.
Knowledge center
Owned educational content connected to this family.
An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data…
Updated October 13, 2026
Why an FDA-approved tirzepatide medicine, a compounded product and a research-use catalog material are not interchangeable evidence categories.
Updated October 1, 2026
Tirzepatide research goes beyond body weight. Two sleep-apnea trials measured breathing interruptions during sleep. Here is how to read their results.
Updated October 5, 2026
A scan substudy separates body weight, fat mass and lean mass.
Updated October 11, 2026Source-traceable evidence
Structured readings of published studies, with the model, result and translation boundary stated explicitly.
What 2,539 participants, three study groups and a placebo comparison tell us.
Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: TR5 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
